Adamas Pharmaceuticals Inc was incorporated in the State of Delaware on November 15, 2000. It is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The Company is developing its wholly-owned product candidate, ADS-5102 (amantadine hydrochloride) for a complication associated with the treatment of Parkinson's disease known as levodopa-induced dyskinesia. The Company's portfolio also includes two drugs commercially available in the United States for indications relating to Alzheimer's disease: Namzaric capsules and Namenda XR extended release capsules.